X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs MYLAN (US) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PFIZER   MYLAN
EQUITY SHARE DATA
    PFIZER
Mar-18
MYLAN
Dec-14
PFIZER/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,3654,285-   
Low Rs1,6253,019-   
Sales per share (Unadj.) Rs430.31,466.8-  
Earnings per share (Unadj.) Rs78.7176.7-  
Cash flow per share (Unadj.) Rs93.2284.4-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.5729.1-  
Shares outstanding (eoy) m45.75378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.62.5 186.2%   
Avg P/E ratio x25.320.7 122.6%  
P/CF ratio (eoy) x21.412.8 166.7%  
Price / Book Value ratio x3.45.0 67.9%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,2711,381,812 6.6%   
No. of employees `0002.625.0 10.5%   
Total wages/salary Rs m3,1430-   
Avg. sales/employee Rs Th7,484.822,199.6 33.7%   
Avg. wages/employee Rs Th1,195.00-   
Avg. net profit/employee Rs Th1,369.12,674.3 51.2%   
INCOME DATA
Net Sales Rs m19,685554,991 3.5%  
Other income Rs m1,143-3,235 -35.3%   
Total revenues Rs m20,828551,756 3.8%   
Gross profit Rs m5,003138,029 3.6%  
Depreciation Rs m66340,762 1.6%   
Interest Rs m423,939 0.0%   
Profit before tax Rs m5,47970,093 7.8%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8782,947 63.7%   
Profit after tax Rs m3,60166,858 5.4%  
Gross profit margin %25.424.9 102.2%  
Effective tax rate %34.34.2 815.3%   
Net profit margin %18.312.0 151.8%  
BALANCE SHEET DATA
Current assets Rs m24,167487,910 5.0%   
Current liabilities Rs m9,544381,448 2.5%   
Net working cap to sales %74.319.2 387.2%  
Current ratio x2.51.3 198.0%  
Inventory Days Days5578 70.6%  
Debtors Days Days29107 26.8%  
Net fixed assets Rs m9,514128,396 7.4%   
Share capital Rs m45819,626 2.3%   
"Free" reserves Rs m26,3750-   
Net worth Rs m26,832275,885 9.7%   
Long term debt Rs m25412,145 0.0%   
Total assets Rs m36,9001,111,240 3.3%  
Interest coverage x1,305.53.9 33,237.6%   
Debt to equity ratio x01.5 0.1%  
Sales to assets ratio x0.50.5 106.8%   
Return on assets %9.88.2 119.6%  
Return on equity %13.424.2 55.4%  
Return on capital %20.413.6 149.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,4660-   
CASH FLOW
From Operations Rs m3,31872,954 4.5%  
From Investments Rs m-2,383-57,534 4.1%  
From Financial Activity Rs m-1,104-19,223 5.7%  
Net Cashflow Rs m-169-3,803 4.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare PFIZER With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare PFIZER With: DR. DATSONS LABS  SUVEN LIFE  ORCHID PHARMA LTD  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 16, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS